Literature DB >> 16156856

Selective apoptosis of natural killer-cell tumours by l-asparaginase.

Miki Ando1, Koichi Sugimoto, Toshiyuki Kitoh, Makoto Sasaki, Kouichi Mukai, Jun Ando, Motoki Egashira, Sheldon M Schuster, Kazuo Oshimi.   

Abstract

We examined the effectiveness of various anti-tumour agents to natural killer (NK)-cell tumour cell lines and samples, which are generally resistant to chemotherapy, using flow cytometric terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labelling (TUNEL) assay. Although NK-YS and NK-92 were highly resistant to various anti-tumour agents, l-asparaginase induced apoptosis in these two NK-cell lines. NK-cell leukaemia/lymphoma and acute lymphoblastic leukaemia (ALL) samples were selectively sensitive to l-asparaginase and to doxorubicin (DXR) respectively. Samples of chronic NK lymphocytosis, an NK-cell disorder with an indolent clinical course, were resistant to both drugs. Our study clearly separated two major categories of NK-cell disorders and ALL according to the sensitivity to DXR and l-asparaginase. We examined asparagine synthetase levels by real-time quantitative polymerase chain reaction (RQ-PCR) and immunostaining in these samples. At least in nasal-type NK-cell lymphoma, there was a good correlation among asparagine synthetase expression, in vitro sensitivity and clinical response to l-asparaginase. In aggressive NK-cell leukaemia, although asparagine synthetase expression was high at both mRNA and protein levels, l-asparaginase induced considerable apoptosis. Furthermore, samples of each disease entity occupied a distinct area in two-dimensional plotting with asparagine synthetase mRNA level (RQ-PCR) and in vitrol-asparaginase sensitivity (TUNEL assay). We confirmed rather specific anti-tumour activity of l-asparaginase against NK-cell tumours in vitro, which provides an experimental background to the clinical use of l-asparaginase for NK-cell tumours.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16156856     DOI: 10.1111/j.1365-2141.2005.05694.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  50 in total

1.  [Expression of asparagine synthetase in relapsed or refractory extranodal NK/T cell lymphoma].

Authors:  Shao-Jie Wu; Yu-Fa Li; Yu-Jue Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2016-04-20

2.  Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation.

Authors:  Fumihiro Ishida; Young Hyeh Ko; Won Seog Kim; Junji Suzumiya; Yasushi Isobe; Kazuo Oshimi; Shigeo Nakamura; Ritsuro Suzuki
Journal:  Cancer Sci       Date:  2012-03-23       Impact factor: 6.716

3.  L-asparaginase-based regimen as a first-line treatment for newly diagnosed nasal type extranodal natural killer cell/T-cell lymphoma.

Authors:  Shanshan Bu; Fangfang Yuan; Xudong Wei; Qingsong Yin; Yufu Li; Ruihua Mi; Haiping Yang; Hongyi Li; Shoubei Ge; Yanyan Liu; Yongping Song
Journal:  Exp Ther Med       Date:  2016-04-11       Impact factor: 2.447

4.  Extranodal NK-T Cell Lymphoma, Nasal Type: Retrospective Analysis of Real-World Data.

Authors:  Sneha J Bothra; Pragya Bhandari; Narendra Agrawal; Narender Tejwani; Rayaz Ahmed; Vishvdeep Khushoo; Sumeet Mirgh; Dinesh Bhurani
Journal:  Indian J Hematol Blood Transfus       Date:  2019-09-28       Impact factor: 0.900

Review 5.  NK/T Cell Lymphoma: Updates in Therapy.

Authors:  Ritsuro Suzuki
Journal:  Curr Hematol Malig Rep       Date:  2018-02       Impact factor: 3.952

6.  Management of advanced NK/T-cell lymphoma.

Authors:  Eric Tse; Yok-Lam Kwong
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

7.  Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up.

Authors:  Liang Wang; Wei-da Wang; Zhong-jun Xia; Yu-jing Zhang; Jin Xiang; Yue Lu
Journal:  Med Oncol       Date:  2014-01-31       Impact factor: 3.064

Review 8.  Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment.

Authors:  Holbrook Kohrt; Ranjana Advani
Journal:  Leuk Lymphoma       Date:  2009-11

Review 9.  Extranodal NK/T-cell lymphoma nasal type: efficacy of pegaspargase. Report of two patients from the United Sates and review of literature.

Authors:  Vincent Edgar Reyes; Tahseen Al-Saleem; Valentin G Robu; Mitchell R Smith
Journal:  Leuk Res       Date:  2009-09-27       Impact factor: 3.156

10.  Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population.

Authors:  Shunan Qi; Joachim Yahalom; Meier Hsu; Monica Chelius; Matthew Lunning; Alison Moskowitz; Steven Horwitz
Journal:  Leuk Lymphoma       Date:  2016-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.